Inventor · Ottawa, ON, CA

John Bell

29Patents
4h-index
41Co-inventors
59Inventor score

Filing activity: Sep 18, 2000 → Apr 10, 2019

Most-cited inventions

PatentTitleAreaCited byStatus
US7731974B2 Mutant vesicular stomatitis viruses and uses thereof Chemistry; Metallurgy 31 Expired
US7192580B2 Purging of cells using viruses Chemistry; Metallurgy 12 Expired
US9045729B2 Oncolytic rhabdovirus Emerging Cross-Sectional Technologies 6 Active
US7582614B2 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection Emerging Cross-Sectional Technologies 5 Expired
US8940291B2 Compositions and methods for enhancing virus efficacy Chemistry; Metallurgy 4 Active
US8227440B2 Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection Emerging Cross-Sectional Technologies 3 Active
US9919047B2 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus Chemistry; Metallurgy 2 Active
US10363293B2 Vaccine composition Chemistry; Metallurgy 2 Active
US10434169B2 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus Chemistry; Metallurgy 1 Active
US8147822B1 Oncolytic virus Chemistry; Metallurgy 1 Expired
US10603351B2 Engineered synergistic oncolytic viral symbiosis Chemistry; Metallurgy 1 Active
US9719105B2 Methods and compositions for production of vaccinia virus Chemistry; Metallurgy 1 Active
US10646557B2 Vaccine composition Chemistry; Metallurgy 0 Active
US8481023B2 Oncolytic rhabdovirus Chemistry; Metallurgy 0 Active
US10767166B2 Methods and compositions for production of vaccina virus Chemistry; Metallurgy 0 Active
US10066214B2 Compositions and methods for enhancing virus replication Emerging Cross-Sectional Technologies 0 Active
US11110138B2 Non-replicating virus-derived particles and uses thereof Chemistry; Metallurgy 0 Active
US9283254B2 Compositions and methods for enhancing virus efficacy Chemistry; Metallurgy 0 Active
US9623096B2 Virally infected hematopoietic cells and uses thereof Chemistry; Metallurgy 0 Active
US11739350B2 MicroRNA-based compositions and methods used in disease treatment Chemistry; Metallurgy 0 Active
US8282917B2 Mutant viruses and uses thereof Chemistry; Metallurgy 0 Active
US9896664B2 Oncolytic rhabdovirus Emerging Cross-Sectional Technologies 0 Active
US9821054B2 Method of vaccination comprising a histone deacetylase inhibitor Chemistry; Metallurgy 0 Active
US11590184B2 Oncolytic rhabdovirus expressing IL12 Chemistry; Metallurgy 0 Active
US10660947B2 Vaccine composition Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.